Professor at Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Prof. Li Dengju is a distinguished researcher and academician in the field of hematology, specializing in acute leukemia. With over 22 years of professional experience, he currently serves as a Professor and Chief Physician in the Department of Hematology at Tongji Hospital, affiliated with Huazhong University of Science and Technology. His research has significantly contributed to the understanding of hematological disorders, with a particular focus on DNMT3A-mutated acute myeloid leukemia (AML). Prof. Dengju is an accomplished mentor, guiding six doctoral and over 20 master’s students, and has published 35 high-impact SCI papers as the first or corresponding author. His innovative findings on CAR-T therapy for AML underline his dedication to advancing personalized immunotherapy. Prof. Dengju’s contributions to clinical research include participation in over 60 international and domestic clinical studies, demonstrating his expertise in translating scientific discoveries into clinical practice.
Professional Profile
Education
Prof. Dengju’s academic journey began with a bachelor’s degree in medicine from Henan Medical University in 1996. He pursued a doctorate in hematology at Huazhong University of Science and Technology, completing it in 2002. His educational background has provided a strong foundation for his groundbreaking research in acute leukemia. As a lifelong learner, Prof. Dengju continuously enriches his knowledge through research and collaborations. Notably, his tenure as a visiting scholar at the University of Pennsylvania School of Medicine from 2010 to 2011 expanded his global academic perspective. These experiences have equipped him with advanced skills in research methodologies, clinical practices, and innovative treatments for hematological disorders. His dedication to academic excellence has been a driving force behind his successful career in both education and research.
Professional Experience
Prof. Dengju began his professional journey as a Deputy Chief Physician and Associate Professor in the Department of Hematology at Tongji Hospital in 2004. Over the years, he has risen to the position of Chief Physician and full Professor, a role he has held since 2011. His leadership in the department has been pivotal in advancing research and clinical care for patients with acute leukemia. In addition to his academic role, Prof. Dengju actively engages in clinical trials, serving as the principal investigator for numerous national and provincial projects. His tenure as a visiting scholar at the University of Pennsylvania further enriched his expertise, enabling him to incorporate international best practices into his work. Through his career, he has combined academic rigor with clinical excellence, making substantial contributions to the field of hematology.
Research Interests
Prof. Dengju’s primary research interests lie in acute leukemia, with a specific focus on DNMT3A-mutated AML. His team’s work explores the molecular mechanisms of this mutation and its impact on the immune microenvironment, leading to groundbreaking discoveries in personalized immunotherapy. His innovative research on CD44v6 CAR-T therapy has opened new avenues for targeted treatments, providing hope for patients with this challenging condition. Prof. Dengju is deeply committed to advancing knowledge in the diagnosis, treatment, and management of hematological disorders. His collaborative approach integrates basic and clinical research, aiming to bridge the gap between laboratory findings and patient care. By focusing on precision medicine, he seeks to develop novel therapies that improve outcomes for leukemia patients worldwide.
Research Skills
Prof. Dengju possesses a comprehensive skill set in hematology research, including advanced diagnostic techniques, molecular biology, and immunotherapy development. His expertise extends to designing and managing large-scale clinical trials, evidenced by his involvement in over 60 studies of new drugs for leukemia. He is adept at grant writing and has successfully secured funding for multiple national and provincial research projects. As a seasoned academic, he excels in mentoring and supervising doctoral and master’s students, fostering the next generation of researchers. His proficiency in publishing high-impact papers reflects his ability to communicate complex scientific findings effectively. Prof. Dengju’s collaborative mindset and interdisciplinary approach enable him to contribute significantly to both basic and translational research in hematology.
Awards and Honors
Throughout his career, Prof. Dengju has received numerous accolades for his contributions to hematology. He has been recognized for his leadership in research and his role in advancing clinical treatments for acute leukemia. His publications in high-impact journals and his successful mentoring of doctoral and master’s students have earned him respect within the academic community. While specific awards and honors are not listed in his application, his achievements in securing competitive research funding and his appointment as a visiting scholar at the University of Pennsylvania highlight his international recognition. Prof. Dengju’s dedication to innovation and excellence in hematology research has established him as a prominent figure in his field.
Conclusion
Prof. Li Dengju is an exemplary candidate for the Best Researcher Award, given his extensive experience, groundbreaking research, and commitment to academic excellence. His innovative work on DNMT3A-mutated AML and CAR-T therapy demonstrates his ability to address critical challenges in hematology. As a leader, mentor, and researcher, Prof. Dengju embodies the qualities of a distinguished scientist dedicated to advancing medical knowledge and improving patient care. His accomplishments not only reflect his expertise but also his unwavering commitment to making meaningful contributions to the scientific community. Prof. Dengju’s remarkable career trajectory and impactful research make him highly deserving of this prestigious recognition.
Publication Top Notes
- Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021
- Authors: Yeming Zhou, Guiqin Huang, Xiaoya Cai, Ying Liu, Bingxin Qian, Dengju Li
- Year: 2024
- DOI: 10.1186/s40364-024-00649-y
- Citations: As this article was published in 2024, citation data may not be available yet.
- XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway
- Authors: Xiaoya Cai, Ying Liu, Huimin Li, Yimei Que, Min Xiao, Ying Wang, Xiong Wang, Dengju Li
- Year: 2024
- DOI: 10.1007/s00277-024-05706-y
- Citations: As this article was published in 2024, citation data may not be available yet.
- Significance of targeting DNMT3A mutations in AML
- Authors: Guiqin Huang, Xiaoya Cai, Dengju Li
- Year: 2024
- DOI: 10.1007/s00277-024-05885-8
- Citations: As this article was published in 2024, citation data may not be available yet.
- An atypical patient with bone marrow failure syndrome‐2 without microcephaly and learning disability in a Chinese family
- Authors: Jia Wu, Jin Wang, Ning Tang, Xiong Wang, Dengju Li
- Year: 2023
- DOI: 10.1111/bjh.18798
- Citations: As this article was published in 2023, citation data may not be available yet.
- The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
- Authors: Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, et al.
- Year: 2023
- DOI: 10.1158/1078-0432.c.6533216
- Citations: As this article was published in 2023, citation data may not be available yet.